Fri, Nov 29, 2024
Volume 17, Issue 2 (Mar-Apr 2023)
mljgoums 2023, 17(2): 14-19 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Zakeri M, alimoradi E, Seyyedhashemi E, Marhamati S, Tajari V, Joshaghani H. Evaluation of Anti-Nuclear Antibodies and Anti-dsDNA Serum Levels in Patients with Suspected Systemic Lupus Erythematosus. mljgoums 2023; 17 (2) :14-19
URL: http://mlj.goums.ac.ir/article-1-1329-en.html
URL: http://mlj.goums.ac.ir/article-1-1329-en.html
Mana Zakeri1 
, Elham Alimoradi2 , Effat Seyyedhashemi3 , Shayan Marhamati4 , Vahid Tajari5 , Hamidreza Joshaghani 6
, Elham Alimoradi2 , Effat Seyyedhashemi3 , Shayan Marhamati4 , Vahid Tajari5 , Hamidreza Joshaghani 6
1- Department of biology, Islamic Azad University, Tehran Medical Branch, Tehran, Iran
2- Department of biology ,faculty of science ,Razi university ,kermanshah ,iran
3- Department of Molecular Medicine, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran
4- department of Biochemistry, golestan University of Medical Sciences, Gorgan, Iran
5- Student Research Committee, Golestan University of Medical Sciences, Gorgan, Iran
6- Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran
2- Department of biology ,faculty of science ,Razi university ,kermanshah ,iran
3- Department of Molecular Medicine, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran
4- department of Biochemistry, golestan University of Medical Sciences, Gorgan, Iran
5- Student Research Committee, Golestan University of Medical Sciences, Gorgan, Iran
6- Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran
Abstract: (2083 Views)
Background and objectives: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, caused by abnormal innate and adaptive immune responses. Anti-nuclear antibodies (ANA) and anti-double stranded DNA (anti-dsDNA) are reliable biomarkers for diagnosing SLE. Here, we aimed to investigate the serum levels of anti-dsDNA and ANA antibodies, their diagnostic utilities, and their relationship with disease activity and clinical/laboratory manifestations in patients with suspected.
Methods: We evaluated the plasma levels of ANA and anti-dsDNA antibodies in all individuals with suspected SLE (n=668) who had been referred to rheumatology clinics in Gorgan, Iran. The level of antibodies as well as C3, C4, and CH50 were determined using commercially available enzyme-linked immunosorbent assay kits.
Results: The mean level of ANA and anti-dsDNA antibodies differed significantly between the ANA-positive and ANA-negative groups (p<0.001). However, there was no significant difference in the mean values of C3 (p=0.233), C4 (p=0.415, and CH50 (p=0.482) between the two groups. Moreover, there was a significant positive correlation between ANA and anti-dsDNA levels (p<0.001, r=0.50).
Conclusion: Our findings indicate that anti-dsDNA levels are higher in ANA-positive individuals, and there may be a positive correlation between ANA and anti-dsDNA levels. It is recommended to evaluate the diagnostic and prognostic values of ANA and anti-dsDNA antibodies in future studies.
Methods: We evaluated the plasma levels of ANA and anti-dsDNA antibodies in all individuals with suspected SLE (n=668) who had been referred to rheumatology clinics in Gorgan, Iran. The level of antibodies as well as C3, C4, and CH50 were determined using commercially available enzyme-linked immunosorbent assay kits.
Results: The mean level of ANA and anti-dsDNA antibodies differed significantly between the ANA-positive and ANA-negative groups (p<0.001). However, there was no significant difference in the mean values of C3 (p=0.233), C4 (p=0.415, and CH50 (p=0.482) between the two groups. Moreover, there was a significant positive correlation between ANA and anti-dsDNA levels (p<0.001, r=0.50).
Conclusion: Our findings indicate that anti-dsDNA levels are higher in ANA-positive individuals, and there may be a positive correlation between ANA and anti-dsDNA levels. It is recommended to evaluate the diagnostic and prognostic values of ANA and anti-dsDNA antibodies in future studies.
Keywords: Antibodies, Antinuclear [MeSH], Lupus Erythematosus, Systemic [MeSH], ELISA [MeSH], Diagnosis [MeSH]
Research Article: Original Paper |
Subject:
Microbiology
Received: 2020/09/16 | Accepted: 2021/06/16 | Published: 2023/03/14 | ePublished: 2023/03/14
Received: 2020/09/16 | Accepted: 2021/06/16 | Published: 2023/03/14 | ePublished: 2023/03/14
References
1. Mok C, Lau C. Pathogenesis of systemic lupus erythematosus. Journal of clinical pathology. 2003; 56(7): 481-90. [View at Publisher] [DOI:10.1136/jcp.56.7.481] [PubMed] [Google Scholar]
2. Gergianaki I, Bortoluzzi A, Bertsias G. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. Best Practice & Research Clinical Rheumatology. 2018; 32(2): 188-205. [View at Publisher] [DOI:10.1016/j.berh.2018.09.004] [PubMed] [Google Scholar]
3. Kuhn A, Bonsmann G, Anders H-J, Herzer P, Tenbrock K, Schneider M. The diagnosis and treatment of systemic lupus erythematosus. Deutsches Ärzteblatt International. 2015;112(25):423. [DOI:10.3238/arztebl.2015.0423] [PubMed] [Google Scholar]
4. Jamshidi A-R, Tehrani-Banihashemi A, Dahaghin S, Gholami J, Froozanfar M-H, Akhlaghi M, et al. Clinical hand osteoarthritis in Tehran: prevalence, signs, symptoms, and pattern-COPCORD Stage I, Iran Study. The Journal of rheumatology. 2008;35(7):1467-9. [View at Publisher] [PubMed] [Google Scholar]
5. Tedeschi SK, Bermas B, Costenbader KH. Sexual disparities in the incidence and course of SLE and RA. Clinical Immunology. 2013;149(2):211-8. [View at Publisher] [DOI:10.1016/j.clim.2013.03.003] [PubMed] [Google Scholar]
6. Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. The Journal of experimental medicine. 2005; 201(5): 703-11. [View at Publisher] [DOI:10.1084/jem.20042251] [PubMed] [Google Scholar]
7. Smith PP, Gordon C. Systemic lupus erythematosus: clinical presentations. Autoimmunity reviews. 2010;10(1):43-5. [View at Publisher] [DOI:10.1016/j.autrev.2010.08.016] [PubMed] [Google Scholar]
8. Aringer M. EULAR/ACR classification criteria for SLE. Semin Arthritis Rheum. 2019; 49(3S): S14-S17. [DOI:10.1016/j.semarthrit.2019.09.009] [PubMed]
9. Gheita T, Abaza N, Hammam N, Mohamed A, El-Gazzar I, Eissa A. Anti-dsDNA titre in female systemic lupus erythematosus patients: relation to disease manifestations, damage and antiphospholipid antibodies. Lupus. 2018;27(7):1081-7. [View at Publisher] [DOI:10.1177/0961203318760209] [PubMed] [Google Scholar]
10. Ighe A, Dahlström Ö, Skogh T, Sjöwall C. Application of the 2012 Systemic Lupus International Collaborating Clinics classification criteria to patients in a regional Swedish systemic lupus erythematosus register. Arthritis research & therapy. 2015;17(1):1-8. [View at Publisher] [DOI:10.1186/s13075-015-0521-9] [PubMed] [Google Scholar]
11. Isenberg D, Manson J, Ehrenstein M, Rahman A. Fifty years of anti-ds DNA antibodies: are we approaching journey's end? 2007. [View at Publisher] [DOI:10.1093/rheumatology/kem112] [PubMed] [Google Scholar]
12. Fu SM, Dai C, Zhao Z, Gaskin F. Anti-dsDNA Antibodies are one of the many autoantibodies in systemic lupus erythematosus. F1000Research. 2015;4(F1000 Faculty Rev). [View at Publisher] [DOI:10.12688/f1000research.6875.1] [PubMed] [Google Scholar]
13. Bragazzi NL, Watad A, Damiani G, Adawi M, Amital H, Shoenfeld Y. Role of anti-DNA auto-antibodies as biomarkers of response to treatment in systemic lupus erythematosus patients: hypes and hopes. Insights and implications from a comprehensive review of the literature. Expert review of molecular diagnostics. 2019;19(11):969-78. [View at Publisher] [DOI:10.1080/14737159.2019.1665511] [PubMed] [Google Scholar]
14. Herbst R, Liu Z, Jallal B, Yao Y. Biomarkers for systemic lupus erythematosus. Int J Rheum Dis. 2012; 15(5): 433-44. [DOI:10.1111/j.1756-185X.2012.01764.x] [PubMed]
15. Gensous N, Marti A, Barnetche T, Blanco P, Lazaro E, Seneschal J, et al. Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review. Arthritis research & therapy. 2017;19(1):1-12. [View at Publisher] [DOI:10.1186/s13075-017-1442-6] [PubMed] [Google Scholar]
16. Mohammadi S, Sedighi S, Memarian A. IL-17 is aberrantly overexpressed among under-treatment systemic lupus erythematosus patients. Iranian journal of pathology. 2019;14(3):236. [View at Publisher] [DOI:10.30699/IJP.2019.94878.1934] [PubMed] [Google Scholar]
17. Pisetsky DS, Bossuyt X, Meroni PL. ANA as an entry criterion for the classification of SLE. Autoimmunity reviews. 2019;18(12):102400. [View at Publisher] [DOI:10.1016/j.autrev.2019.102400] [PubMed] [Google Scholar]
18. Granito A, Muratori L, Tovoli F, Muratori P. Diagnostic role of anti-dsDNA antibodies: do not forget autoimmune hepatitis. Nature Reviews Rheumatology. 2021;17(4):244-. [View at Publisher] [DOI:10.1038/s41584-021-00573-7] [PubMed] [Google Scholar]
19. Bardin N, Desplat-Jego S, Daniel L, Jourde Chiche N, Sanmarco M. BioPlex™ 2200 multiplexed system: Simultaneous detection of anti-dsDNA and anti-chromatin antibodies in patients with systemic lupus erythematosus. Autoimmunity. 2009; 42(1): 63-8. [View at Publisher] [DOI:10.1080/08916930802354906] [PubMed] [Google Scholar]
20. Infantino M, Grossi V, Benucci M, Li Gobbi F, Damiani A, Manfredi M. The impact of biological treatments on the anti-dsDNA and anti-nucleosome tests. Lupus. 2018;27(1):40-8. [View at Publisher] [DOI:10.1177/0961203317709344] [PubMed] [Google Scholar]
21. Almogren A. Anti-double stranded antibody. Association with titers and fluorescence patterns of anti-nuclear antibody in systemic lupus erythematosus. Saudi Med J. 2010;31(1):32-6. [PubMed] [Google Scholar]
22. Fatemi A, Matinfar M, Sayedbonakdar Z, Maracy M, Karimzadeh H, Saber M, et al. Outcome of adult onset systemic lupus erythematosus in Iran. Lupus. 2014; 23(11): 1211-6. [View at Publisher] [DOI:10.1177/0961203314534304] [PubMed] [Google Scholar]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Enamad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.